The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
E1308: Reduced-dose IMRT in human papilloma virus (HPV)-associated resectable oropharyngeal squamous carcinomas (OPSCC) after clinical complete response (cCR) to induction chemotherapy (IC).
Anthony Cmelak
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Shuli Li
No relevant relationships to disclose
Shanthi Marur
Research Funding - Bristol-Myers Squibb
Weiqiang Zhao
No relevant relationships to disclose
William H. Westra
No relevant relationships to disclose
Christine H. Chung
No relevant relationships to disclose
Maura L. Gillison
No relevant relationships to disclose
Jill Gilbert
No relevant relationships to disclose
Julie E. Bauman
Consultant or Advisory Role - AVEO
Research Funding - Bristol-Myers Squibb; Genentech; Lilly; Novartis; Pfizer
Lynne I. Wagner
No relevant relationships to disclose
Robert L. Ferris
No relevant relationships to disclose
David R. Trevarthen
No relevant relationships to disclose
A. Dimitrios Colevas
No relevant relationships to disclose
Balkrishna N. Jahagirdar
No relevant relationships to disclose
Barbara Burtness
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb